Is Thymosin Alpha-1 Legal in Illinois?

HealthRX.com

Thymosin alpha-1 has no FDA approval and no Illinois-specific rule

Print or save as PDF

  • FDA approval / None; FDA's search found no US application for thymosin alpha-1 [1]
  • Approved as a medicine elsewhere / Italy, India and Hong Kong (Zadaxin) [1]
  • FDA bulks list, state-licensed pharmacies / None of the three categories [2]
  • FDA bulks list, outsourcing facilities / Category 3, nominated without adequate support [3]
  • FDA advisory committee vote, December 4 2024 / 4 yes, 17 no [4]
  • HHS October 2026 peptide policy / Not one of the six peptides covered [5]
  • WADA Prohibited List / Not named on the 2026 or 2027 list [6]

What is its federal status?

FDA's search found no US application for thymosin alpha-1. FDA's December 2024 review notes that it holds four US orphan drug designations, but orphan designation is a separate process from approval and is not an approval [1].

It is an approved medicine in some other countries. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].

Can a US pharmacy compound it?

For state-licensed pharmacies and physicians, thymosin alpha-1 is in none of FDA's three categories. For outsourcing facilities, FDA lists it in category 3, 'nominated without adequate support'. FDA's category 1 policy of generally not acting against compounders does not apply to it [2][3].

It previously sat in category 2, for substances FDA says may present significant safety risks, and now appears in the 'nominated but withdrawn' table after the nominators withdrew [7]. FDA's stated concerns remain posted: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information FDA called inadequate to sufficiently understand the extent of any safety issues [7].

FDA proposed that thymosin alpha-1 not be added to the pharmacy bulks list. On December 4 2024 its Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. The October 2026 HHS draft enforcement-discretion policy covers six other peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500), not thymosin alpha-1 [5]. No FDA or HHS action allowing compounding of it was found [5].

Does Illinois change this?

FDA's categories, the advisory committee vote and the HHS draft policy are federal. This page cites no Illinois statute or rule that names thymosin alpha-1, so the federal position above is what it can state.

Questions worth asking

Choose the questions you want to keep

Is it banned in sport?

Thymosin alpha-1 is not named on WADA's 2026 Prohibited List or in the 2027 List [6]. The substance WADA does name in this family is thymosin-beta-4 and its derivatives such as TB-500, listed under S2.3 growth factors, which is a different peptide [6]. WADA's S0 catch-all covers substances with no approval from any governmental health authority, and thymosin alpha-1 is approved in some countries [6][1].

What is actually sold, and where

Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end; thymalfasin is the synthetic version with the same sequence [1]. Zadaxin is the brand of the finished 1.6 mg injection sold outside the US and is not interchangeable with bulk thymosin alpha-1 powder [1]. Two older reviews, both by authors tied to the Zadaxin developer, say it is approved in 'over 35 countries' (2009) and 'more than 30 countries' (2007) [8][9].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Does FDA's category 1 policy of generally not acting against compounders apply to thymosin alpha-1?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is thymosin alpha-1 legal in Illinois?
It is not FDA-approved, and it is not covered by FDA's category 1 enforcement-discretion policy for state-licensed pharmacies [1][2]. This page cites no Illinois rule that names it.
Can an Illinois compounding pharmacy make thymosin alpha-1?
For outsourcing facilities FDA lists it in category 3, nominated without adequate support [3]. FDA proposed not adding it to the pharmacy bulks list, and its advisory committee voted 4 yes and 17 no [4].
Is thymosin alpha-1 approved anywhere in the world?
Yes. FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people, India for chronic hepatitis B in adults with compensated liver disease and virus replication, and Hong Kong [1]. The EMA holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
Does the October 2026 HHS peptide policy cover thymosin alpha-1?
No. That draft enforcement-discretion policy names six peptides - BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 - and thymosin alpha-1 is not among them [5].
Is thymosin alpha-1 the same as TB-500?
No. WADA names thymosin-beta-4 and its derivatives such as TB-500 as growth factors; thymosin alpha-1 is a different peptide and is not named on the 2026 or 2027 Prohibited List [6].
Did the FDA ever consider allowing thymosin alpha-1 compounding?
FDA proposed that it not be added to the pharmacy bulks list. On December 4 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on both the free base and the acetate, with members who voted no citing no compelling evidence of clinical effectiveness and safety [4].
Show all 9 referencesHide references
Evidence overview for Is Thymosin Alpha-1 Legal in Illinois?